Serumske vrednosti endokana u relaciji sa tradicionalnim i netradicionalnim antropometrijskim parametrima u populaciji odraslih

Endokan i indeksi gojaznosti

  • Aleksandra Klisic
  • Nebojša Kavarić Primary Health Care Center, University of Montenegro-Faculty of Medicine, Podgorica, Montenegro
  • Vesna Spasojević-Kalimanovska Department for Medical Biochemistry, University of Belgrade - Faculty of Pharmacy, Belgrade, Serbia
  • Jelena Kotur-Stevuljević Department for Medical Biochemistry, University of Belgrade - Faculty of Pharmacy, Belgrade, Serbia
  • Ana Ninić Department for Medical Biochemistry, University of Belgrade - Faculty of Pharmacy, Belgrade, Serbia
DOI: https://doi.org/10.5937/jomb0-25170
Ključne reči: kardiometabolički rizik, endokan, inflamacija, gojaznost

Sažetak


Uvod i Cilj: Povezanost endokana sa netradicionalnim antropometrijskim parametrima, kao različitim faktorima rizika za kardiovaskularne bolesti, nije ispitivana u prethodnim studijama. Endokan je novi biomarker inflamacije, čije su veće vrednosti zabeležene kod kardiometaboličkih poremećaja. Znajući da je gojaznost nezavisan faktor rizika za mnoga kardiometabolička oboljenja, cilj je bio da se ispita povezanost endokana i novih antropometrijskih pokazatelja [tj. body adiposity index (BAI), cardiometabolic index (CMI), a body shape index, body roundness index, conicity index, lipid accumulation product index i visceral adiposity index] i onih tradicionalnih [tj. obim struka, obim kukova, indeks telesne mase, odnos obim struka/telesna visina, odnos obim struka/obim kukova] u populaciji odraslih.
Metode: Ukupno 177 ispitanika je učestvovalo u istraživanju. Antropometrijski i biohemijski parametri su mereni.
Rezultati: Univarijantna regresiona analiza je pokazala pozitivnu korelaciju endokana i skoro svih ispitivanih antropometrijskih parametara. U cilju daljeg ispitivanja postojanja nezavisnih korelacija endokana i antropometrijskih parametara, kreiran je Model koji je zadovoljio kriterijume za ordinalnu regresiju. Prilagođeni odds-ovi za BAI u Modelu (OR=1,120, 95% CI 1,036-1,212, P=0,004), su pokazali da je porast BAI za 1 jedinicu povećao verovatnoću za porast koncentracije endokana za 12%. Takođe, porast CMI za 1 jedinicu, povećao je verovatnoću za veće vrednosti endokana za 2,6 puta (OR=2,599, 95% CI 1,006-6,712, P=0,049). Ukupno 20,1% varijabiliteta u vrednostima koncentracije endokana može biti objašnjeno ovim Modelom.
Zaključak: Netradicionalni pokazatelji gojaznosti, BAI i CMI, su nezavisno povezani sa većim vrednostima endokana u populaciji odraslih.

Reference

1. Zhao T, Kecheng Y, Zhao X, Hu X, Zhu J, Wang Y, Ni J. The higher serum endocan levels may be a risk factor for the onset of cardiovascular disease: A meta-analysis. Medicine (Baltimore) 2018; 97(49): e13407. doi: 10.1097/MD.0000000000013407
2. Klisic A, Kavaric N, Stanisic V, Vujcic S, Spasojevic-Kalimanovska V, Ninic A, Kotur-Stevuljevic J. Endocan and a novel score for dyslipidemia, oxidative stress and inflammation (DOI score) are independently correlated with glycated hemoglobin (HbA1c) in patients with prediabetes and type 2 diabetes. Arch Med Sci 2020; 16(1): 42-50. doi: https://doi.org/10.5114/aoms.2019.87541
3. Ekiz-Bilir B, Bilir B, Aydın M, Soysal-Atile N. Evaluation of endocan and endoglin levels in chronic kidney disease due to diabetes mellitus. Arch Med Sci 2019; 15(1): 86-91.
4. Klisic A, Kavaric N, Abenavoli L, Stanisic V, Spasojevic-Kalimanovska V, Kotur-Stevuljevic J, Ninic A. Is endocan a novel potential biomarker of liver steatosis and fibrosis? J Med Biochem 2020; 39(3): 363-71. doi: 10.2478/jomb-2019-0042
5. Oktar SF, Guney I, Eren S, Oktar L, Kosar K, Buyukterzi Z, et al. Serum endocan levels, carotid intima-media thickness and microalbuminuria in patients with newly diagnosed hypertension. Clin Exp Hypertens 2019; 1-8. doi: 10.1080/10641963.2019.1652632
6. Maksimovic M, Vlajinac H, Radak Dj, Marinkovic J, Maksimovic J, Jorga J. Association of overweight and obesity with cardiovascular risk factors in patients with atherosclerotic diseases. J Med Biochem 2020; 39(2): 215-23. doi: https://doi.org/10.2478/jomb-2019-0027.
7. Klisic A, Isakovic A, Kocic G, Kavaric N, Jovanovic M, Zvrko E, et al. Relationship between Oxidative Stress, Inflammation and Dyslipidemia with Fatty Liver Index in Patients with Type 2 Diabetes Mellitus. Exp Clin Endocrinol Diabetes. 2018; 126(06): 371-8. doi: 10.1055/s-0043-118667
8. Ates E, Set T, Karahan SC, Biçer C, Erel Ö. Thiol/disulphide homeostasis, ischemia modified albumin, and ferroxidase as oxidative stress markers in women with obesity with insulin resistance. J Med Biochem 2019; 38(4): 445-51. doi: 10.2478/jomb-2019-0015
9. Bego T, Čaušević A, Dujić T, Malenica M, Velija-Asimi Z, Prnjavorac B, et al. Association of FTO gene variant (rs8050136) with type 2 diabetes and markers of obesity, glycaemic control and inflammation. J Med Biochem 2019; 38: 153-63. doi: 10.2478/jomb-2018-0023.
10. Ragino YI , Shramko VS , Stakhneva EM , Chernyak EI , Morozov SV , Shakhtshneider EV, et al. Changes in the blood fatty-acid profile associated with oxidative-antioxidant disturbances in coronary atherosclerosis. J Med Biochem 2020; 39(1): 46-53. doi: https://doi.org/10.2478/jomb-2019-0010
11. Sayın S, Kutlu R, Kulaksızoğlu M. The relationship between sex steroids, insulin resistance and body compositions in obese women: A case-control study. J Med Biochem 2020; 39 (1): 25-31. doi: https://doi.org/10.2478/jomb-2019-0009
12. Naghizadeh M, Saghafi-Asl M, Amiri P, Karamzad N. Lipid profile in relation to inflammatory and insulin resistance markers and anthropometric indices in the apparently healthy abdominally obese. Prog Nutr 2019;21(1-S):370-7.
13. Moradi M, Alvandi E, Koohdani F. The Effect of obesity and weight loss through calorie restriction on HDL function. Prog Nutr 2019;21(1-S):16-24.
14. Janke J, Engeli S, Gorzelniak K, Feldpausch M, Heintze U, Böhnke J, et al. Adipose tissue and circulating endothelial cell specific molecule-1 in human obesity. Horm Metab Res 2006; 38(1):28–33. doi:10.1055/s-2006-924973
15. Delibas IB, Yapca OE, Laloglu E. Does endocan level increase in women with polycystic ovary syndrome? A case - control study. Ginekol Pol. 2018;89(9):500-5. doi: 10.5603/GP.a2018.0085
16. Yilmaz MI, Siriopol D, Saglam M, Kurt YG, Unal HU, Eyileten T, et al. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int 2014; 86(6): 1213-20. doi: 10.1038/ki.2014.227
17. Musialowska D, Zbroch E, Koc-Zorawska E, Musialowski P, Malyszko J. Endocan Concentration in Patients With Primary Hypertension. Angiology 2018; 69(6):483-9. doi: 10.1177/0003319717736158
18. Rodrigues KF, Pietrani NT, Bosco AA, Sousa LP, Ferreira CN, Sandrim VC, et al. Endocan: a new biomarker associated with inflammation in type 2 diabetes mellitus? Diabetes Metab Res Rev 2015;31(5):479-80. doi: 10.1002/dmrr.2639
19. Elkamshoushi AM, Omar SS, El Abd AM, Hassan SZ, Sultan EA, Abd Elkawy E. Subclinical atherosclerosis in psoriatic disease: relation to endocan, TNF-α, age of onset, and body fat. Int J Dermatol 2019; 58(4): 456-64. doi: 10.1111/ijd.14290
20. Gungor A, Palabiyik SS, Bayraktutan Z, Dursun H, Gokkaya N, Bilen A, et al. Levels of endothelial cell-specific molecule-1 (ESM-1) in overt hypothyroidisim. Endocr Res. 2016; 41(4):275-2 80. doi: 10.3109/07435800.2015.1135443
21. Bicer M, Guler A, Unal Kocabas G, Imamoglu C, Baloglu A, Bilgir O, et al. Endocan is a predictor of increased cardiovascular risk in women with polycystic ovary syndrome. Endocr Res 2017; 42(2): 145-53. doi: 10.1080/07435800.2016.1255896
22. Wang H, Chen Y, Sun G, Jia P, Qian H, Sun Y. Validity of cardiometabolic index, lipid accumulation product, and body adiposity index in predicting the risk of hypertension in Chinese population. Postgrad Med 2018; 130(3): 325-33. doi: 10.1080/00325481.2018.1444901
23. Bergman RN, Stefanovski D, Buchanan TA, Sumner AE, Reynolds JC, Sebring NG, et al. A better index of body adiposity. Obesity (Silver Spring) 2011; 19: 1083–9.
24. Thomas DM, Bredlau C, Bosy-Westphal A, Mueller M, Shen W, Gallagher D, et al. Relationships between body roundness with body fat and visceral adipose tissue emerging from a new geometrical model. Obesity (Silver Spring) 2013; 21: 2264–71.
25. Valdez R. A simple model-based index of abdominal adiposity. J Clin Epidemiol 1991; 44: 955-6.
26. Krakauer NY, Krakauer JC. A new body shape index predicts mortality hazard independently of body mass index. PLoS ONE 2012; 7: e39504.
27. Wakabayashi I, Daimon T. The "cardiometabolic index" as a new marker determined by adiposity and blood lipids for discrimination of diabetes mellitus. Clin Chim Acta 2015; 438: 274-8. doi: 10.1016/j.cca.2014.08.042
28. Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, et al. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 2010; 33: 920-2.
29. Kahn HS. The "lipid accumulation product" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord 2005; 5: 26.
30. Liu XZ, Li HH, Huang S, Zhao DB. Association between hyperuricemia and nontraditional adiposity indices. Clin Rheumatol 2019; 38(4): 1055-62. doi: 10.1007/s10067-018-4374-x
31. Almeida RT, Pereira ADC, Fonseca MJMD, Matos SMA, Aquino EML. Association between body adiposity index and coronary risk in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Clin Nutr 2019; pii: S0261-5614(19)30252-3. doi: 10.1016/j.clnu.2019.06.001
32. Wakabayashi I, Daimon T. Comparison of discrimination for cardio-metabolic risk by different cut-off values of the ratio of triglycerides to HDL cholesterol. Lipids Health Dis 2019; 18(1): 156. doi: 10.1186/s12944-019-1098-0
33. Wellner M, Herse F, Janke J, Gorzelniak K, Engeli S, Bechart D, et al. Endothelial cell specific molecule-1--a newly identified protein in adipocytes. Horm Metab Res 2003; 35(4): 217-21. doi: 10.1055/s-2003-39477
34. Delehedde M, Devenyns L, Maurage CA, Vivès RR. Endocan in cancers: a lesson from a circulating dermatan sulfate proteoglycan. Int J Cell Biol 2013; 2013: 705027. doi: 10.1155/2013/705027
35. Murthi P, Sarkis R, Lim R, Nguyen-Ngo C, Pratt A, Liong S, et al. Endocan expression is increased in the placenta from obese women with gestational diabetes mellitus. Placenta 2016; 48: 38-48. doi: 10.1016/j.placenta.2016.10.003
36. Lee W, Ku SK, Kim SW, Bae JS. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol 2014; 229: 620-30.
Objavljeno
2020/05/28
Broj časopisa
Vol. 40 Br. 1 (2021): Journal of Medical Biochemistry
Rubrika
Original paper

Sva prava zadržana (c) 2020 Aleksandra Klisic, Nebojsa Kavaric, Vesna Spasojevic-Kalimanovska, Jelena Kotur-Stevuljevic, Ana Ninic

Creative Commons License

Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.